Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 14/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9095612 | 0.85 | DRD2 (0.45) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL2611661 | 0.84 | KDM4E (0.47) | KDM4ECYP1A2CYP2C19GAASMN1; SMN2 | |
| SCHEMBL11379691 | 0.84 | DRD2 (0.56) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL12119031 | 0.78 | ADRB2 (0.59) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL13313354 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL2796726 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL29153234 | 0.77 | MAPT (0.59) | KDM4ELMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL12559617 | 0.77 | CA12 (0.47) | DRD2DRD4DRD3KDM4ECYP1A2 | |
| SCHEMBL30437983 | 0.77 | CA12 (0.47) | KDM4ELMNACYP2C19GAASMN1; SMN2 | |
| SCHEMBL10215350 | 0.77 | ADRB2 (0.65) | DRD2ADRB2ADRB1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
| WO-2018059537-A1 | DIAZASPIRO[5.5]UNDECANE DERIVATIVE AND USE THEREOF | 四川海思科制药有限公司 | 2018-04-05 | — | — | WO | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2017125060-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | 四川海思科制药有限公司 | 2017-07-27 | — | — | WO | disclosed |
| WO-2017114377-A1 | BENZYL HETEROCYCLIC COMPOUND DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2017-07-06 | — | — | WO | disclosed |
| WO-2017107877-A1 | BIPHENYL DERIVATIVE AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2017-06-29 | — | — | WO | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-7294650-B2 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-11-13 | — | — | US | disclosed |
| US-7294650-B2 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-11-13 | — | — | US | disclosed |
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20070172385-A1 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-20070172385-A1 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | DRD2 373/4885DRD4 1506/4885DRD3 1023/4885 |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | DRD2 388/4885DRD4 1613/4885DRD3 1138/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | DRD2 373/4885DRD4 1506/4885DRD3 1023/4885 |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | DRD2 388/4885DRD4 1613/4885DRD3 1138/4885 |
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | DRD2 254/4885DRD4 867/4885DRD3 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.